Status: Not yet recruiting
UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases
This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in With Relapse/Refractory Autoimmune Diseases.
Participants needed: 18
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Changzhou No.2 People's HospitalUpdated: May 18, 2025Locations: 1
Eligibility criteria
1.Age ≥ 18 years old (inclusive), regardless of gender. [+8]
1.Subjects with a history of severe drug allergies or allergic constitutions; [+8]